Moderna to Present at Upcoming Conferences in May 2026
Rhea-AI Summary
Moderna (Nasdaq: MRNA) will present at three investor conferences in May 2026: BofA Securities Healthcare Conference on May 12, 2026 at 11:20 AM PT, PTRBC Global Healthcare Conference on May 19, 2026 at 10:00 AM ET, and Bernstein Strategic Decisions Conference on May 28, 2026 at 10:00 AM ET.
Live webcasts will be available in the Investors > Events and Presentations section at investors.modernatx.com, and replays will be archived for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – MRNA
In the Apr 21 session, MRNA declined 0.66%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 17 | Oncology trial data | Positive | -1.8% | Phase 1/2 melanoma data with high ORR and FDA Fast Track designation. |
| Apr 15 | Earnings date set | Neutral | +2.7% | Announcement of Q1 2026 earnings release and corporate update call. |
| Apr 06 | Vaccine data update | Positive | +2.8% | Revaccination data for flu vaccine mRNA-1010 and RSV vaccine mRESVIA. |
| Mar 03 | Patent settlement | Positive | +16.0% | Global settlement with Arbutus/Genevant and clarified cash/liquidity outlook. |
| Feb 27 | Regulatory opinion | Positive | +3.6% | EMA CHMP positive opinion for mCOMBRIAX combination vaccine in EU adults. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often triggered positive price reactions, especially around regulatory wins and major settlements, with one notable divergence on strong oncology trial data.
Over the last few months, Moderna has reported several important developments. A Feb 27, 2026 EMA CHMP positive opinion on mCOMBRIAX saw shares rise 3.6%. The Mar 3, 2026 global patent settlement with Arbutus/Genevant, involving a $950 million payment and potential $1.3 billion contingent amount, coincided with a 15.99% gain. Subsequent vaccine data and an earnings-date announcement in April produced modest gains, while strong Phase 1/2 oncology data on Apr 17, 2026 led to a -1.76% pullback, showing occasional divergence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
BofA Securities 2026 Healthcare Conference, on Tuesday, May 12th at 11:20am PT
RBC 2026 Global Healthcare Conference, on Tuesday, May 19th at 10:00 am ET
Bernstein's 42nd Annual Strategic Decisions Conference, Thursday, May 28th at 10:00am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire